Recombinant human brain natriuretic peptide

ApprovedPeptide

SShanghai Jiao Tong University School of Medicine

Recombinant human brain natriuretic peptide is one of 87 small molecule programs targeting Tetralogy of Fallot. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tetralogy of FallotActive, not recruiting

Pulmonary HypertensionActive, not recruiting

Septic ShockActive, not recruiting

Heart FailureActive, not recruiting

Tetralogy of FallotPreclinical

Active, not recruiting

Pulmonary HypertensionApproved

Active, not recruiting

Septic ShockPreclinical

Active, not recruiting

Heart FailurePreclinical

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Recombinant human brain natriuretic peptide

SShanghai Jiao Tong University School of Medicine

Approved

1 2

Bayer Aspirin

Bayer

Preclinical

2 3

Medrol

Pfizer

Preclinical

1 4

Monoferric

PPharmacosmos A/S

Preclinical

5 5

Activase

Roche

Preclinical

—6

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 7

Zoloft

VViatris Specialty LLC

Preclinical

2 8

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 9

Adriamycin

GGynecologic Oncology Group

Preclinical

—10

Neo-Synephrine

EExela Pharma Sciences, LLC.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/ANot yet recruiting

Septic Shock

NCT06745206

Clinical

Trials by Indication[1]

Heart Failure1 trial

Preliminary Study on the Clinical Effect of Recombinant Human Brain Natriuretic Peptide on Sepsis Complicated With Heart Failure

Unknown status·SShanghai Zhongshan Hospital·N/A·NCT05111769·70 enrolled

Not yet recruiting·SSichuan Provincial People's Hospital·N/A·NCT06745206·30 enrolled

Pulmonary Hypertension1 trial

rhBNP in Type 3 Pulmonary Hypertension

Unknown status·SShengjing Hospital·Phase 4·NCT05716984·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Recombinant human brain natriuretic peptide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant human brain natriuretic peptide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant human brain natriuretic peptide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Jiao Tong University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Approved[1]
Company: SShanghai Jiao Tong University School of Medicine

Recombinant human brain natriuretic peptide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Heart Failure1 trial

Percutaneous Coronary Intervention1 trial

Tetralogy of Fallot1 trial

Septic Shock1 trial

Pulmonary Hypertension1 trial

References

Drug Info

Quick Facts

Related News